Therapeutic Category
Anti-diabetic
EMZORA
Targeted SGLT2 Inhibition for Diabetes and Heart Failure
Anti-diabetic Brand
EMZORA
EMZORA contains empagliflozin, a selective SGLT2 inhibitor that helps improve glycaemic control and provides cardiovascular and renal benefits in eligible adults.
Dosage form
Tablets
Strengths Available
10mg, 25mg
Pack sizes
Pack of 3x10 Tablets
Therapeutic Indications
- EMZORA is indicated for improving glycaemic control in adults with type 2 diabetes mellitus and for the treatment of heart failure and chronic kidney disease, including reduction of associated cardiovascular and renal risks.
Packshot not available
Brand Name
EMZORA
Product Name
EMZORA 10
Generic Name
Empagliflozin Tablets 10mg
Dosage Form
Tablets
Pack Size
Pack of 3x10 Tablets
Therapeutic Indication
EMZORA 10mg is indicated to improve glycaemic control in adults with type 2 diabetes mellitus, used with diet and exercise, alone or in combination with other blood-glucose-lowering medicines, including insulin.
Dosage and Method of Administration
Adults: 10mg once daily,
Mode of Administration
For oral use only.
Packshot not available
Brand Name
EMZORA
Product Name
EMZORA 25
Generic Name
Empagliflozin Tablets 25mg
Dosage Form
Tablets
Pack Size
Pack of 3x10 Tablets
Therapeutic Indication
EMZORA 25mg is indicated to improve glycaemic control in adults with type 2 diabetes mellitus, used with diet and exercise, alone or in combination with other blood-glucose-lowering medicines, including insulin.
Dosage and Method of Administration
Adults: 25mg once daily, for type 2 diabetes mellitus when additional glycaemic control is required.
Mode of Administration
For oral use only.